Novo Nordisk’s Diabetes Franchise Bears The Weight Of Disappointing Obesity Sales

As Manufacturing Issues Continue

 
• By Ayisha Sharma

The Danish firm’s GLP-1 drugs are behind much of its 2021 sales success as ongoing problems with the manufacturing of in-demand obesity product Wegovy dampen growth.  

Diabetes monitoring and healthcare. Close up top down view of glucose meter, drug pills and syringe on blue background with copy space.
Novo Is Known For Its Diabetes Franchise But Wegovy Is Touted As A Blockbuster Obesity Drug. • Source: Alamy

More from Earnings

More from Business